Emily Jones is professor of translational neurodevelopment at the Centre for Brain and Cognitive Development at Birkbeck, University of London in the United Kingdom. Her research efforts center on the neurodevelopmental pathways that lead to autism. She is involved with a number of early-intervention studies for infants with siblings with autism and attention deficit hyperactivity disorder.
Emily Jones
Professor
Birkbeck, University of London
From this contributor
Connecting autism-linked genetic variation to infant social behavior
Integrating genetic analyses into studies of babies’ brain development could help us understand how autism-related genes contribute to autism traits.
Connecting autism-linked genetic variation to infant social behavior
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.